Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Significant Increase in Short Interest

Posted by Francis Steltz on Sep 18th, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,668,357 shares, an increase of 56.3% from the August 15th total of 1,067,589 shares. Currently, 4.5% of the shares of the stock are short sold. Based on an average daily volume of 35,561,049 shares, the days-to-cover ratio is currently 0.0 days.

Insider Activity

In related news, Director Luke Evnin sold 107,429 shares of Werewolf Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total transaction of $33,302.99. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 23.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HOWL. Bank of America Corp DE purchased a new position in shares of Werewolf Therapeutics during the second quarter valued at $112,000. Squarepoint Ops LLC bought a new stake in Werewolf Therapeutics during the 2nd quarter valued at $37,000. Finally, BlackRock Inc. purchased a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth $37,000. Institutional investors own 64.84% of the company’s stock.

Analyst Ratings Changes

HOWL has been the subject of several research analyst reports. Weiss Ratings upgraded Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Werewolf Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.00.

Check Out Our Latest Report on HOWL

Werewolf Therapeutics Stock Up 4.8%

Shares of NASDAQ:HOWL opened at $0.96 on Friday. The firm has a fifty day simple moving average of $0.62 and a two-hundred day simple moving average of $0.62. The stock has a market capitalization of $46.80 million, a P/E ratio of -1.27 and a beta of 0.51. Werewolf Therapeutics has a 52 week low of $0.27 and a 52 week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The firm had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $21.00 million. On average, analysts expect that Werewolf Therapeutics will post -0.89 earnings per share for the current year.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company uses its proprietary INDUKINE platform to design conditionally activated cytokines, which are intended to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues.

Werewolf’s pipeline has included WTX-124, an investigational interleukin-2 therapy designed to promote the expansion and activation of immune cells in tumors, and WTX-330, an investigational interleukin-12 therapy intended to activate both innate and adaptive immune responses.